These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25786656)

  • 1. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
    Cardoso HJ; Vaz CV; Correia S; Figueira MI; Marques R; Maia CJ; Socorro S
    Prostate; 2015 Jun; 75(9):923-35. PubMed ID: 25786656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The G-quadruplex ligand, SYUIQ-FM05, targets proto-oncogene c-kit transcription and induces apoptosis in K562 cells.
    Shen FH; Jin J; Li J; Wang Y; Zhu SH; Lu YJ; Ou TM; Huang ZS; Huang M; Huang ZY
    Pharm Biol; 2013 Apr; 51(4):447-54. PubMed ID: 23363047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
    Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor imatinib modulates the viability and apoptosis of castrate-resistant prostate cancer cells dependently on the glycolytic environment.
    Cardoso HJ; Vaz CV; Carvalho TMA; Figueira MI; Socorro S
    Life Sci; 2019 Feb; 218():274-283. PubMed ID: 30605651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
    Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
    Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration.
    Popow-Woźniak A; Woźniakowska A; Kaczmarek L; Malicka-Błaszkiewicz M; Nowak D
    Eur J Pharmacol; 2011 Sep; 667(1-3):66-73. PubMed ID: 21658383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
    Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
    Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia.
    Imura M; Kojima Y; Kubota Y; Hamakawa T; Yasui T; Sasaki S; Hayashi Y; Kohri K
    Prostate; 2012 Oct; 72(14):1506-13. PubMed ID: 22314612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells.
    Zhao D; Lin F; Wu X; Zhao Q; Zhao B; Lin P; Zhang Y; Yu X
    Toxicol In Vitro; 2012 Jun; 26(4):595-602. PubMed ID: 22388098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
    Litz J; Krystal GW
    Mol Cancer Ther; 2006 Jun; 5(6):1415-22. PubMed ID: 16818499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
    Sambol EB; Ambrosini G; Geha RC; Kennealey PT; Decarolis P; O'connor R; Wu YV; Motwani M; Chen JH; Schwartz GK; Singer S
    Cancer Res; 2006 Jun; 66(11):5858-66. PubMed ID: 16740725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.